vs
Side-by-side financial comparison of Ladder Capital Corp (LADR) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Ladder Capital Corp is the larger business by last-quarter revenue ($22.3M vs $18.6M, roughly 1.2× SCYNEXIS INC). Ladder Capital Corp runs the higher net margin — 71.0% vs 65.7%, a 5.3% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -18.0%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -22.5%).
Ladder Capital Corp is a leading commercial real estate finance firm operating primarily across the United States. It originates and manages a diversified portfolio of senior secured commercial mortgage loans, mezzanine debt, commercial mortgage-backed securities, and direct real estate assets, serving property owners, operators and developers across major market segments.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
LADR vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $22.3M | $18.6M |
| Net Profit | $15.9M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 69.5% | 56.3% |
| Net Margin | 71.0% | 65.7% |
| Revenue YoY | -18.0% | 1808.5% |
| Net Profit YoY | -49.4% | 376.5% |
| EPS (diluted) | $0.13 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $22.3M | $18.6M | ||
| Q3 25 | $27.8M | $334.0K | ||
| Q2 25 | $21.5M | $1.4M | ||
| Q1 25 | $20.3M | $257.0K | ||
| Q4 24 | $27.2M | $977.0K | ||
| Q3 24 | $38.4M | $660.0K | ||
| Q2 24 | $34.3M | $736.0K | ||
| Q1 24 | $37.1M | $1.4M |
| Q4 25 | $15.9M | $12.3M | ||
| Q3 25 | $19.2M | $-8.6M | ||
| Q2 25 | $17.1M | $-6.9M | ||
| Q1 25 | $11.6M | $-5.4M | ||
| Q4 24 | $31.3M | — | ||
| Q3 24 | $27.6M | $-2.8M | ||
| Q2 24 | $32.1M | $-14.5M | ||
| Q1 24 | $16.4M | $411.0K |
| Q4 25 | 69.5% | 56.3% | ||
| Q3 25 | 72.4% | -2516.5% | ||
| Q2 25 | 96.7% | -701.0% | ||
| Q1 25 | 52.7% | -3350.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | 74.1% | -1563.6% | ||
| Q2 24 | 90.4% | -1255.0% | ||
| Q1 24 | 49.4% | -692.5% |
| Q4 25 | 71.0% | 65.7% | ||
| Q3 25 | 69.0% | -2572.2% | ||
| Q2 25 | 79.5% | -504.8% | ||
| Q1 25 | 56.8% | -2097.7% | ||
| Q4 24 | 115.1% | — | ||
| Q3 24 | 71.7% | -425.5% | ||
| Q2 24 | 93.6% | -1964.4% | ||
| Q1 24 | 44.2% | 29.9% |
| Q4 25 | $0.13 | $0.25 | ||
| Q3 25 | $0.15 | $-0.17 | ||
| Q2 25 | $0.14 | $-0.14 | ||
| Q1 25 | $0.09 | $-0.11 | ||
| Q4 24 | $0.25 | — | ||
| Q3 24 | $0.22 | $-0.06 | ||
| Q2 24 | $0.26 | $-0.30 | ||
| Q1 24 | $0.13 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $38.0M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.5B | $49.4M |
| Total Assets | $5.2B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $38.0M | $40.0M | ||
| Q3 25 | $49.4M | $37.9M | ||
| Q2 25 | $134.9M | $44.8M | ||
| Q1 25 | $479.8M | $40.6M | ||
| Q4 24 | $1.3B | $59.3M | ||
| Q3 24 | $1.6B | $68.8M | ||
| Q2 24 | $1.2B | $73.0M | ||
| Q1 24 | $1.2B | $80.2M |
| Q4 25 | $1.5B | $49.4M | ||
| Q3 25 | $1.5B | $36.4M | ||
| Q2 25 | $1.5B | $44.5M | ||
| Q1 25 | $1.5B | $50.5M | ||
| Q4 24 | $1.5B | $55.1M | ||
| Q3 24 | $1.5B | $58.5M | ||
| Q2 24 | $1.5B | $60.4M | ||
| Q1 24 | $1.5B | $74.1M |
| Q4 25 | $5.2B | $59.0M | ||
| Q3 25 | $4.7B | $51.1M | ||
| Q2 25 | $4.5B | $60.7M | ||
| Q1 25 | $4.5B | $67.9M | ||
| Q4 24 | $4.8B | $90.6M | ||
| Q3 24 | $4.8B | $99.0M | ||
| Q2 24 | $4.8B | $107.8M | ||
| Q1 24 | $5.3B | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $87.0M | $18.4M |
| Free Cash FlowOCF − Capex | $78.7M | — |
| FCF MarginFCF / Revenue | 352.4% | — |
| Capex IntensityCapex / Revenue | 37.4% | — |
| Cash ConversionOCF / Net Profit | 5.49× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $118.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.0M | $18.4M | ||
| Q3 25 | $26.3M | $-8.7M | ||
| Q2 25 | $44.0M | $-7.5M | ||
| Q1 25 | $-28.7M | $-7.5M | ||
| Q4 24 | $133.9M | $-24.0M | ||
| Q3 24 | $169.0M | $765.0K | ||
| Q2 24 | $45.4M | $-10.9M | ||
| Q1 24 | $-20.4M | $-4.0M |
| Q4 25 | $78.7M | — | ||
| Q3 25 | $25.9M | — | ||
| Q2 25 | $43.4M | — | ||
| Q1 25 | $-29.6M | — | ||
| Q4 24 | $127.4M | — | ||
| Q3 24 | $166.0M | — | ||
| Q2 24 | $44.9M | — | ||
| Q1 24 | $-21.7M | — |
| Q4 25 | 352.4% | — | ||
| Q3 25 | 93.1% | — | ||
| Q2 25 | 201.6% | — | ||
| Q1 25 | -145.6% | — | ||
| Q4 24 | 468.2% | — | ||
| Q3 24 | 432.1% | — | ||
| Q2 24 | 131.0% | — | ||
| Q1 24 | -58.6% | — |
| Q4 25 | 37.4% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | 2.9% | — | ||
| Q1 25 | 4.3% | — | ||
| Q4 24 | 23.9% | — | ||
| Q3 24 | 7.8% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | 3.7% | — |
| Q4 25 | 5.49× | 1.50× | ||
| Q3 25 | 1.37× | — | ||
| Q2 25 | 2.57× | — | ||
| Q1 25 | -2.49× | — | ||
| Q4 24 | 4.27× | — | ||
| Q3 24 | 6.13× | — | ||
| Q2 24 | 1.41× | — | ||
| Q1 24 | -1.24× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LADR
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
